ANGIOTENSIN CONVERTING ENZYME-INHIBITORS FOR REDUCTION OF PROTEINURIA IN CHILDREN WITH STEROID-RESISTANT NEPHROTIC SYNDROME

被引：27

作者：

MILLINER, DS

MORGENSTERN, BZ

机构：

[1] Department of Pediatrics and Division of Nephrology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota

来源：

PEDIATRIC NEPHROLOGY | 1991年 / 5卷 / 05期

关键词：

PROTEINURIA; NEPHROTIC SYNDROME; ANGIOTENSIN CONVERTING ENZYME INHIBITORS; RENAL FUNCTION;

D O I：

10.1007/BF00856646

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

The effects of angiotensin converting enzyme inhibitors (ACEI) on proteinuria, renal function, and serum proteins were evaluated in six children with steroid-resistant nephrotic syndrome and proteinuria of 3 - 15 g/24 h (277 +/- 47 mg/m2 per hour). Following ACEI, proteinuria decreased from 7,408 +/- 2,385 (mean +/- SEM) to 3,746 +/- 1,395 mg/24 h (P < 0.05). Creatinine clearance was 87.8 +/- 22.6 before and 96.4 +/- 23.6 ml/min per 1.73 m2 after ACEI. In two patients, inulin and para-aminohippuric acid clearances were normal before and after ACEI, together with parallel reductions of urine protein of 50% and 46%. Clearance of total protein was reduced by 56% following ACEI, compared with reduction in the clearance of gamma globulin by 58% and albumin by 39.5%. No significant change was seen in blood pressure, serum albumin, or total protein following ACEI. After ACEI, diuretic doses were able to be reduced or eliminated in three patients. Reduction of proteinuria was sustained during a followup period of 11 - 20 months in three patients. ACEI may be of benefit in the clinical management of children with steroid-resistant nephrotic syndromes, allowing reduction in diuretic requirements.

引用

页码：587 / 590

页数：4

共 32 条

[1]

Bernard D.B., Extrarenal complications of the nephrotic syndrome, Kidney Int, 33, pp. 1184-1202, (1988)

[2]

Velosa J.A., Holley K.E., Torres V.E., Offord K.P., Significance of proteinuria on the outcome of renal function in patients with focal segmental glomerulosclerosis, Mayo Clin Proc, 58, pp. 568-577, (1983)

[3]

Beaufils H., Alphonse J.C., Guedon J., Legrain M., Focal glomerulosclerosis: natural history and treatment: a report of 70 cases, Nephron, 21, pp. 75-85, (1978)

[4]

Korbet S.M., Schwartz M.M., Lewis E.J., The prognosis of focal segmental glomerular sclerosis of adulthood, Medicine, 65, pp. 304-311, (1986)

[5]

Whelton A., Stout R.L., Spilman P.S., Klassen D.K., Renal effects of ibuprofen, priroxicam, and sulindac in patients with asymptomatic renal failure, Ann Intern Med, 112, pp. 568-576, (1990)

[6]

Walser M., Progression of chronic renal failure in man, Kidney Int, 37, pp. 1195-1210, (1990)

[7]

Abraham P.A., Opsahl J.A., Halstenson C.E., Keane W.F., Efficacy and renal effects of enalapril therapy for hypertensive patients with chronic renal insufficiency, Arch Interm Med, 148, pp. 2358-2362, (1988)

[8]

Mazzuca N., Bigazzi R., Paparatto P., Setti G.P., Valtriani C., Falciani C., Chiapponi I., Bianchi S., Morini V., Baldari G., Effects of enalapril on urinary protein excretion of essential and renal parenchymal hypertensive patients, J Nucl Med Allied Sci, 32, pp. 75-81, (1988)

[9]

Taguma Y., Kitamoto Y., Futaki G., Ueda H., Monma H., Ishizaki M., Takahashi H., Sekino H., Sasaki Y., Effect of captopril on heavy proteinuria in azotemic diabetics, N Engl J Med, 313, pp. 1617-1620, (1985)

[10]

Kisch E.S., Captopril and proteinuria in diabetes mellitus, Isr J Med Sci, 23, pp. 833-834, (1987)

← 1 2 3 4 →